Brief: Biofrontera Submits Study Report Of Pharmacokinetics Study To FDA
24/02/2021 13:31
Feb 24 (Reuters) - BIOFRONTERA AG B8FGn.DE :
* BIOFRONTERA SUBMITS STUDY REPORT OF PHARMACOKINETICS STUDY
TO
FDA
* APPLICATION IS SUPPORTED BY A PHASE I PHARMACOKINETICS
(PK)
STUDY FOR TREATMENT OF ACTINIC KERATOSES WITH THREE TUBES OF
AMELUZ®.
Source text for Eikon: ID:nPexcS8Rfa
Further company coverage: B8FGn.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))
Recent news on Biofrontera AG
See all newsBrief: Biofrontera Says Co And Units Have Entered Into An Agreement With Biofrontera Inc About How To Settle Payment Obligations By Biofrontera Inc
Brief: Biofrontera AG Says Legal Dispute On Import In USA Will Result In Revised Outlook
Brief: Biofrontera AG Resolves Capital Increase From Authorized Capital
Brief: Biofrontera AG Says Plans Capital Reduction And Considers Subsequent Capital Increase From Authorized Capital
Brief: Biofrontera AG Says FY 2022 Total Revenue Amounted To EUR 25.7 Million